Analysts Set Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Target Price at $15.25

Rani Therapeutics Holdings, Inc. (NASDAQ:RANIGet Free Report) has been assigned an average recommendation of “Buy” from the six ratings firms that are covering the company, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $14.00.

Several analysts have weighed in on the company. Canaccord Genuity Group lowered their price target on Rani Therapeutics from $21.00 to $9.00 and set a “buy” rating on the stock in a report on Wednesday, March 27th. Wedbush reissued an “outperform” rating and set a $8.00 price objective on shares of Rani Therapeutics in a report on Tuesday, February 6th. Finally, HC Wainwright decreased their price objective on Rani Therapeutics from $16.00 to $12.00 and set a “buy” rating on the stock in a report on Monday, March 25th.

Check Out Our Latest Analysis on RANI

Rani Therapeutics Stock Performance

NASDAQ:RANI opened at $3.11 on Wednesday. The business’s 50-day moving average price is $3.47 and its two-hundred day moving average price is $2.87. Rani Therapeutics has a twelve month low of $1.82 and a twelve month high of $5.81. The stock has a market cap of $156.00 million, a P/E ratio of -2.34 and a beta of 0.97. The company has a quick ratio of 6.36, a current ratio of 6.36 and a debt-to-equity ratio of 0.96.

Hedge Funds Weigh In On Rani Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Stifel Financial Corp boosted its position in shares of Rani Therapeutics by 84.9% during the third quarter. Stifel Financial Corp now owns 141,904 shares of the company’s stock valued at $309,000 after purchasing an additional 65,144 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in Rani Therapeutics by 83.7% in the second quarter. Tower Research Capital LLC TRC now owns 7,048 shares of the company’s stock worth $29,000 after purchasing an additional 3,211 shares during the period. Renaissance Technologies LLC grew its stake in Rani Therapeutics by 114.5% in the second quarter. Renaissance Technologies LLC now owns 88,201 shares of the company’s stock worth $363,000 after purchasing an additional 47,084 shares during the period. JPMorgan Chase & Co. grew its stake in Rani Therapeutics by 352.2% in the second quarter. JPMorgan Chase & Co. now owns 6,525 shares of the company’s stock worth $27,000 after purchasing an additional 5,082 shares during the period. Finally, Susquehanna International Group LLP purchased a new stake in Rani Therapeutics in the first quarter worth $365,000. 30.19% of the stock is currently owned by institutional investors.

About Rani Therapeutics

(Get Free Report

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including large molecules, such as peptides, proteins, and antibodies.

Featured Articles

Analyst Recommendations for Rani Therapeutics (NASDAQ:RANI)

Receive News & Ratings for Rani Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rani Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.